Saturday, October 31, 2026

Gyrodyne Soars 13% Higher Today: Investors Rejoice!

ViaNews Editorial Team

January 31, 2024

Gyrodyne Soars 13% Higher Today: Investors Rejoice!
(VIANEWS) - Gyrodyne shares saw an unexpected 11.99% surge to EUR9.65 during early trading on Wednesday morning after four consecutive losing days, contributing to an overall decline of 1.28% on NASDAQ which stood at EUR15,315.56; Gyrodyne closed last trading at EUR9.45 which is 25.36% below its 52-week high of EUR12.66.

About Gyrodyne

Gyrodyne LLC is a real estate company located in New York metropolitan area that owns and manages an assortment of office, industrial and service properties. Their flagship property is a 63-acre site on Long Island that includes industrial and office buildings as well as undeveloped land that may become eligible for value-enhancing entitlements in future plans. Gyrodyne also owns a medical office park in Cortlandt Manor that recently filed an application for subdivision. Their common shares trade on NASDAQ Stock Market under symbol GYRO.

Yearly Analysis

Gyrodyne's stock has experienced 52-week high and low values of EUR12.66 (52-week high) and EUR7.80 (52-week low). As of 12:27 EST, Gyrodyne currently sits at an equity value of EUR9.65 which is EUR3.01 below its 52-week high and EUR2.85 above its 52-week low respectively.

Technical Analysis

Gyrodyne stock has experienced price fluctuations recently, currently surpassing both its 50-day moving average of EUR9.46 and 200-day moving average of EUR9.81. Today's reported volume of 3015 was 556.86% higher than its average volume of 459. Volatility for this stock has been unpredictable, with an intraday variation average being negative 5.71% for the last week, negative 0.53% for the month, and positive 2.84% for the quarter. Gyrodyne stock experienced its highest average weekly volatility over the last week at 5.71%; over month at 1.82% and quarter-on-quarter volatility was measured at 2.84%. Gyrodyne's stochastic oscillator, an indicator of overbought and oversold conditions, has classified Gyrodyne's shares as overbought (>=80), which may signal overvaluation and require price adjustment in near future.

Equity Analysis

EPS and PE Ratio are two crucial financial metrics used to assess a company's profitability and valuation. Earnings Per Share (EPS) measures the distribution of net income among outstanding shares of common stock by dividing net income by their outstanding shares, representing how much each shareholder would gain if all the company profits were distributed equally among them. A higher EPS indicates a company is producing greater profits per share - this should be seen as positive sign. Price to Earnings Ratio (PE Ratio) is a valuation metric used to measure how the price of stock compares with earnings per share for any given company. A high PE Ratio indicates that investors are willing to pay more per euro earned, possibly signalling their high expectations for future growth at that company. Gyrodyne boasts a trailing 12-month earnings per share (EPS) of EUR0.21, and a PE ratio of 45.97. This indicates that investors are willing to pay EUR45.97 for every euro of annual earnings generated, representing an expensive valuation for Gyrodyne. When considering its PE ratio, investors should also take into account both current and projected earnings growth potential when making their judgment. More news about Gyrodyne (GYRO).
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com